Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer
- PMID: 17100158
- DOI: 10.1016/j.clon.2006.08.003
Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancer
Abstract
Aims: Epidermal growth factor receptor (EGFR) is expressed by over 70% of muscle-invasive bladder tumours and is associated with diminished overall survival. In model tumour systems, ionising radiation has been shown to activate EGFR, leading to cellular proliferation and is therefore a possible mechanism of underlying radioresistance. We carried out an immunohistochemical study relating the clinical outcome of patients receiving radical radiotherapy for muscle-invasive bladder cancer to tumour EGFR status.
Materials and methods: Archived paraffin-embedded tumours from 110 consecutive patients receiving radical radiotherapy for muscle-invasive bladder cancer between 1991 and 1997 were immunohistochemically stained for EGFR. Data were collected concerning the tumour stage and grade, the presence of ureteric obstruction, the response to radiotherapy at 3 months, local recurrence rates, metastatic spread and survival. Multivariate analysis of potential independent prognostic factors of impaired bladder cancer-specific survival was carried out using Cox's regression.
Results: Of 110 tumours, 79 (72%) stained positively for EGFR. Of 87 patients undergoing the 3-month check cystoscopy, 60 (69%) had a positive response to radiotherapy. A positive response to radiotherapy correlated significantly with a negative EGFR status (chi(2) test, P = 0.05). Kaplan-Meier survival analysis revealed a trend towards improved bladder cancer-specific survival in EGFR-negative patients (Log-rank, P = 0.10). A lack of response to radiotherapy at 3 months, local recurrence, metastatic spread and the presence of ureteric obstruction were all independent prognostic factors for diminished bladder cancer-specific survival (Cox's regression: P = 0.009, P = 0.001, P = 0.04 and P = 0.005, respectively).
Conclusions: EGFR status predicts the local response to radiotherapy but does not provide prognostic utility in relation to overall or bladder cancer-specific survival. As EGFR status seems to be linked to the initial response to radiotherapy, its inhibition may be a means of enhancing the radio-responsiveness of these poor prognosis tumours. Colquhoun, A. J.
Similar articles
-
Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis.Br J Cancer. 1994 Jun;69(6):1120-5. doi: 10.1038/bjc.1994.220. Br J Cancer. 1994. PMID: 7911031 Free PMC article.
-
Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy.Urology. 1996 Mar;47(3):305-10. doi: 10.1016/s0090-4295(99)80443-9. Urology. 1996. PMID: 8633392 Clinical Trial.
-
Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment.Radiother Oncol. 1998 Nov;49(2):149-55. doi: 10.1016/s0167-8140(98)00089-9. Radiother Oncol. 1998. PMID: 10052880
-
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].Actas Urol Esp. 2003 Feb;27(2):132-41. doi: 10.1016/s0210-4806(03)72891-5. Actas Urol Esp. 2003. PMID: 12731328 Review. Spanish.
-
Epidermal growth factor receptor and bladder cancer.Postgrad Med J. 2002 Oct;78(924):584-9. doi: 10.1136/pmj.78.924.584. Postgrad Med J. 2002. PMID: 12415079 Free PMC article. Review.
Cited by
-
TUXEDO: A phase I/II trial of cetuximab with chemoradiotherapy in muscle-invasive bladder cancer.BJU Int. 2022 Jul 31;131(1):63-72. doi: 10.1111/bju.15864. Online ahead of print. BJU Int. 2022. PMID: 35908256 Free PMC article.
-
Role of tyrosine kinases in bladder cancer progression: an overview.Cell Commun Signal. 2020 Aug 14;18(1):127. doi: 10.1186/s12964-020-00625-7. Cell Commun Signal. 2020. PMID: 32795296 Free PMC article. Review.
-
Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo.Med Sci Monit. 2018 Aug 20;24:5811-5819. doi: 10.12659/MSM.909865. Med Sci Monit. 2018. PMID: 30125265 Free PMC article.
-
Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer.BMC Cancer. 2009 Jan 26;9:32. doi: 10.1186/1471-2407-9-32. BMC Cancer. 2009. PMID: 19171060 Free PMC article.
-
Growth factors and receptors as prognostic markers in urothelial carcinoma.Curr Urol Rep. 2008 Jan;9(1):55-61. doi: 10.1007/s11934-008-0011-6. Curr Urol Rep. 2008. PMID: 18366975 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous